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Sir,
In 1998 a letter was published in the British Journal of Cancer
(Lehrer et al, 1998) reporting increased frequency of the
apolipoprotein E ε 4 allele among patients with prostate cancer, and
thereby suggests this allele as a risk factor for this type of cancer.
Lehrer’s study was based on examining 35 patients with prostate
cancer. A study from Finland (n = 130) (Niemi et al, 2000) did not
show evidence that any ApoE-phenotype is associated with
prostate cancer. 
The study of Lehrer (1998) is one of many reports which claims
association between ApoE and particular diseases. The ApoE ε 4
allele is a strong risk factor for Alzheimer’s disease (Strittmatter
et al, 1993), and has been reported to be responsible for progres-
sion of atherosclerosis (Hixson et al, 1991), amyloidosis in patient
with rheumatoid arthritis (Hasegawa et al, 1996), macro- and
microangiopathy in diabetic patients (Ukkola et al, 1993) and
decreased fertility (Gerdes et al, 1996). Finally, ApoE4 has been
reported to have a protective effect against distal colon cancer
(Kervinen et al., 1996). 
It has been shown that the presence of ApoE has a protective
effect on cells in culture due to an anti-oxidative effect, and that the
ApoE2 has the largest protective effect, while ApoE4 is the least
efficient phenotype for protecting cells from oxidative stress. Since
the antioxidant vitamin E has been reported to have a protective
effect against prostate cancer (Hartman et al, 1998), it seems
reasonable to test the hypothesis that the ε 4-allele is a risk factor
for prostate cancer. 
We have examined the hypothesis by comparing the distribution
of apoE genotypes in 230 Norwegian patients (< 70 years) with
prostate cancer to the distribution found in a recent study of 798
Norwegian blood donors (Kumar et al, submitted). ApoE-
genotyping was carried out by polymerase chain reaction (Hixson
and Vernier, 1990). The frequency of the ε 4-allele in the patient
population was 0.187, while the frequency of the ε 4-allele in the
control population was 0.198. This implies that there is no signifi-
cant difference between the prostate cancer population and the
normal population with respect to the frequency of the ε 4-allele.
The ε 4/ε 4-homozygosity appeared at a rate of 0.036 in the prostate
cancer population, while a rate of 0.040 was observed for the
normal Norwegian population (Kumar et al, submitted). This
difference is also non-significant. 
In conclusion, our data do not support the hypothesis that the
ε 4-allele is a risk factor for prostate cancer. 
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